Company news
Gossamer Bio, Inc. news in 2025
Gossamer Bio, Inc.'s news releases, calls and decks from 2025, newest first.
Gossamer Bio to Participate in Upcoming Investor Conferences
November 23, 2025
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
November 4, 2025
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
September 24, 2025
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
September 21, 2025
Gossamer Bio to Present at Upcoming Investor Conferences
August 28, 2025
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update
August 4, 2025
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH
June 15, 2025
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study
May 14, 2025
Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025
May 11, 2025
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference
May 6, 2025
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
March 12, 2025
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
January 27, 2025
Calls in 2025
Decks in 2025
- Q1 2025 Earnings Presentation
Earnings · 43 slides · May 15, 2025